Trimethobenzamide

Source: Wikipedia, the free encyclopedia.
Trimethobenzamide
Clinical data
Trade namesTigan, Tebamide
AHFS/Drugs.comMonograph
MedlinePlusa682693
Routes of
administration		Oral, rectal, intramuscular
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60-100%
Elimination half-life7 to 9 hours (mean)
Excretionurine (30-50%), faeces
Identifiers
  • N-{[4-(2-dimethylaminoethoxy)phenyl]methyl}-
    3,4,5-trimethoxy-benzamide
JSmol)
SMILES
  • O=C(c1cc(OC)c(OC)c(OC)c1)NCc2ccc(OCCN(C)C)cc2
  • InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24) checkY
  • Key:FEZBIKUBAYAZIU-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Trimethobenzamide (trade names Tebamide, Tigan) is an antiemetic used to prevent nausea and vomiting.

Mechanism of action

Trimethobenzamide is an

D2 receptor.[1] It is believed to affect the chemoreceptor trigger zone (CTZ) of the medulla oblongata to suppress nausea and vomiting
.

Side effects

Possible side effects include drowsiness, dizziness, headache, muscle cramps, and blurred vision. More serious adverse effects include skin rash, tremors, parkinsonism, and jaundice.

Formulations

Trimethobenzamide is marketed under the brand names Tebamide and Tigan, manufactured by

GlaxoSmithKline and King Pharmaceuticals
, respectively. It is available as oral capsules and injectable formulations.

Trimethobenzamide was also available as a rectal suppository, but such formulations were banned by the U.S. Food and Drug Administration on April 6, 2007, due to unproven efficacy.[2]

Synthesis

Hoffmann La Roche, U.S. patent 2,879,293
(1959).

Alkylation of the sodium salt of p-hydroxybenzaldehyde (1) with 2-dimethylaminoethyl chloride affords the ether (2). Reductive amination of the aldehyde in the presence of ammonia gives diamine (3). Acylation of that product with 3,4,5-trimethoxybenzoyl chloride affords trimethobenzamide (4).

See also

References

  1. PMID 25841474
    .
  2. ^ Waknine, Yael (April 6, 2007). "FDA Bans Suppositories With Trimethobenzamide". Medscape. Retrieved 2007-04-06.[dead link]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Trimethobenzamide&oldid=1268131185"